Back to Results

Volitionrx Ltd (VNRX)

VolitionRx Ltd is a common stock listing on the NYSE for VolitionRx Limited, a multinational healthcare company focused on epigenetics-based diagnostics. The company develops blood tests intended to detect and monitor multiple cancers as well as diseases linked to NETosis across the United States, Europe, and Asia. Its product and development portfolio includes Nu.Q Vet for cancer screening in animals, Nu.Q Nets for identifying NETosis-related conditions such as sepsis, Nu.Q Discover for nucleosome profiling, Nu.Q Cancer for supporting cancer treatment response and disease monitoring, and Capture-PCR and Capture-Seq for isolating circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-VNRX
$1.61
39.0% Upside
Undervalued
$16.97 1,362.6% Upside
—
Bargain
Weak
—
—
—
0.0%
August 19, 2026
-0.4x
-0.3x
3.9x
9.413 M
16.878 M
59.3%
79.9%
-50.7
—
84.4%
Valuation • Fair Value

Volitionrx Ltd (NYSE-VNRX) Fair Value by Valuation Model

Compare the primary fair value estimate for Volitionrx Ltd (NYSE-VNRX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.61

Estimated upside of 39.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.61

Comparable-company valuation reference.

Analyst Price Target

$16.97 1,362.6% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Volitionrx Ltd (NYSE-VNRX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Volitionrx Ltd (NYSE-VNRX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

2.466 M

Current operating scale indicator.

Revenue Forecast

2.482 M

Forward revenue estimate.

EBITDA

-20.627 M

Current operating profitability reference.

EBITDA Forecast

-12 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Volitionrx Ltd (NYSE-VNRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Volitionrx Ltd (NYSE-VNRX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-4.10

No elevated caution signal from this screen.

Altman Z-Score

-50.7

Lower score that deserves closer risk review.

FCF / Net Income

84.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Volitionrx Ltd (NYSE-VNRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Volitionrx Ltd (NYSE-VNRX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 19, 2026

Days to Earnings

29

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Volitionrx Ltd (NYSE-VNRX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Volitionrx Ltd (NYSE-VNRX) Stock Forecast & Technical Outlook

Review Volitionrx Ltd (NYSE-VNRX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Volitionrx Ltd (NYSE-VNRX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Volitionrx Ltd (NYSE-VNRX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Volitionrx Ltd (NYSE-VNRX) has a Strong Buy consensus, with 3 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 1
Sell 0
FAQ • Fast Investor Answers

Volitionrx Ltd (NYSE-VNRX) Stock FAQ

Quick answers about Volitionrx Ltd (NYSE-VNRX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.61
Estimated upside 39.0%
Valuation Rating
Undervalued
Estimated upside of 39.0%
Analyst Target
$16.97 1,362.6% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Volitionrx Ltd (NYSE-VNRX) is $1.61. This implies an estimated upside of 39.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 39.0% versus the current market price.

The available analyst price target for Volitionrx Ltd (NYSE-VNRX) is $16.97 1,362.6% Upside.

The current financial health read for Volitionrx Ltd (NYSE-VNRX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Volitionrx Ltd (NYSE-VNRX) is August 19, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Volitionrx Ltd (NYSE-VNRX) is -0.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Volitionrx Ltd is 9.413 M.

The current enterprise value listed for Volitionrx Ltd is 16.878 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Volitionrx Ltd is NYSE-VNRX, and the stock is listed on NYSE.

Volitionrx Ltd (NYSE-VNRX) is listed on NYSE.

The current debt-to-total-capital ratio listed for Volitionrx Ltd is 59.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Volitionrx Ltd is 79.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)